Vertex Pharmaceuticals Incorporated has agreed to acquire Crinetics Pharmaceuticals Inc. for $85 per share in cash, representing a total equity value of approximately $10 billion, or $8.8 billion net of cash acquired. The transaction, unanimously approved by the boards of both companies, adds Crinetics' commercialized and Phase 3 endocrinology assets to Vertex's portfolio. Vertex expects the acquisition to close in the third quarter of 2026, subject to regulatory approvals and Crinetics shareholder approval.

Strategic Rationale and Assets

The acquisition centers on two key assets. PALSONIFY (paltusotine) is the first and only once-daily oral therapy for adults with acromegaly, a rare condition affecting an estimated 20,000 diagnosed people in the U.S. Approved by the U.S. Food and Drug Administration in September 2025 and recently by the European Medicines Agency, the drug has demonstrated strong early uptake since launch. Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist, is currently in Phase 3 development for congenital adrenal hyperplasia (CAH). Classic CAH has 17,000 addressable patients in the U.S. In Phase 2 studies, patients taking atumelnant achieved near normalization of excess androgen levels on physiologic replacement doses of glucocorticoids.

Financial Impact

Vertex expects the transaction to contribute immediately to revenue growth through the ongoing launch of PALSONIFY. The company projects that at peak, these assets could deliver more than $5 billion in combined annual revenue, supporting a goal of sustained double-digit revenue growth and industry-leading operating margins. The deal is expected to become accretive to adjusted operating income in 2029.

Transaction Terms

Vertex plans to finance the acquisition using a combination of cash on hand and debt, supported by $4.5 billion of fully committed bridge financing from Bank of America, N.A. and Morgan Stanley Senior Funding, Inc. Vertex’s cash, cash equivalents, and total marketable securities as of March 31, 2026, were $13.0 billion.

Transaction Overview

Leadership and Analyst Commentary

Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex, described Crinetics as an excellent strategic fit due to its focus on serious diseases with significant unmet need. William Blair noted that this is the first time the firm has heard of a multi-billion dollar sales potential for a CAH product. Analyst Myles Minter stated that while the deal is on the higher side regarding stock price premium, it is viewed as reasonable if the peak sales number can be achieved. The firm believes significantly more of the >$5 billion peak sales potential is weighted toward the atumelnant opportunity, which carries more risk given its late-clinical-stage nature.

Vertex Pharmaceuticals signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a triple combination therapy for cystic fibrosis (CF). The agreement aims to improve access to the treatment for approximately 3,800 eligible patients across Canada, including up to 60 individuals receiving a medicine that treats the underlying cause of their disease for the first time. This LOI follows positive reimbursement recommendations issued by Canada's Drug Agency (CDA-AMC) in December 2025 and Institut national d'excellence en santé et services sociaux (INESSS) in April 2026.

Agreement Details

The LOI marks a step toward public listing of ALYFTREK through publicly funded drug programs. Vertex will now initiate discussions with provinces and territories to finalize the process. The therapy is designed for patients aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Therapy Overview

ALYFTREK combines vanzacaftor, tezacaftor, and deutivacaftor to address the defective CFTR protein. Vanzacaftor and tezacaftor facilitate the processing and trafficking of the CFTR protein to the cell surface, while deutivacaftor acts as a potentiator to improve salt and water flow across the cell membrane. The therapy is approved in the United States, United Kingdom, European Union, Canada, New Zealand, Switzerland, and Australia.

Safety Considerations

Elevated transaminases have been observed in some patients treated with ALYFTREK. Cases of liver failure leading to transplantation and death have been reported in patients taking a fixed-dose combination drug containing tezacaftor and ivacaftor, which shares active ingredients with ALYFTREK. Liver injury has primarily been reported within the first six months of treatment initiation.